OKYO Pharma Appoints Ophthalmology Veteran Robert Dempsey as New CEO

OKYO Pharma Ltd (NASDAQ:OKYO), the NASDAQ‑listed clinical‑stage biopharmaceutical company focused on eye disease treatments, has named seasoned ophthalmology executive Robert Dempsey as its new Chief Executive Officer, effective immediately. Dempsey will also join OKYO’s board of directors as an executive director. Outgoing CEO Gary Jacob will transition into the role of Chief Development Officer while remaining on the board, ensuring leadership continuity. OKYO said the leadership change positions the company for accelerated strategic growth, especially around its lead drug candidate urcosimod, which is being developed to address neuropathic corneal pain (NCP) — a severe eye condition with no FDA‑approved therapy — as well as other inflammatory ocular diseases. Dempsey brings over 20 years of global experience in ophthalmology drug development and commercialization. He previously served as Group Vice President and Head of Global Ophthalmology at Shire, where he played a key role in the development and launch of Xiidra, one of the most successful branded dry eye therapies globally. OKYO’s founder and chairman, Gabriele Cerrone, praised Dempsey’s track record and expertise, saying his leadership will help advance OKYO’s clinical and commercial potential. Dempsey expressed enthusiasm about leading the company and building on its strong scientific foundation to address unmet patient needs. #OKYOPharma #LeadershipUpdate #Ophthalmology #BiotechNews #SlimScan #GrowthStocks #CANSLIM